ADVANCED ACCELERATOR APPLICATIONS
- Country
- π«π·France
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.adacap.com
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
- Conditions
- Spondyloarthritis
- Interventions
- Drug: rhAnnexin V-128
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 5
- Registration Number
- NCT03232580
- Locations
- πΊπΈ
Cedars Sinai Medical Center, Los Angeles, California, United States
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Advanced Accelerator Applications
- Registration Number
- NCT02705313
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈUniversity of California, Los Angeles, Los Angeles, California, United States
99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer
- Conditions
- Doxorubicin Induced CardiomyopathyBreast Cancer
- Interventions
- Radiation: 99mTc-rhAnnexin V-128
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 14
- Registration Number
- NCT02677714
- Locations
- π¨π¦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis
- Conditions
- Carotid Artery Plaque
- Interventions
- Radiation: 99mTc-rhAnnexin V-128
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 39
- Registration Number
- NCT02667457
- Locations
- π¨π¦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
- Conditions
- Rheumatoid ArthritisAnkylosing Spondylitis
- Interventions
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 16
- Registration Number
- NCT02328027
- Locations
- π¨π
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers
- Conditions
- Healthy Adult Volunteers
- Interventions
- Drug: Kit for the Preparation of 99mTc-rhAnnexin V-128
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 14
- Registration Number
- NCT02182609
- Locations
- π¨π¦
The University of Ottawa Heart Institute, Ottawa, Ontario, Canada
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
- Conditions
- Neuroendocrine TumourCarcinoid Tumor of the Small Bowel
- Interventions
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 231
- Registration Number
- NCT01578239
- Locations
- πΊπΈ
Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles, California, United States
πΊπΈKettering Medical Center, Kettering, Ohio, United States
πΊπΈNorthwestern Medical Faculty Foundation, Chicago, Illinois, United States
Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Rubidium-82Drug: Sestamibi. reconstitution with sodium pertechnetate (99mTc)
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 135
- Registration Number
- NCT01379677
- Locations
- π¬π§
University College Hospital London NHS Foundation Trust, London, United Kingdom